cyrilzakka/clinical-trials huggingface dataset:
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.

Approximately twenty-four (24) subjects with suspected PDAC and scheduled to undergo surgical resection within 30 days (but not before 24 hours) after the transabdominal BR55 CEUS examination will be enrolled into 3 dose groups, 0.03, 0.05, and 0.08 mL/kg, with a maximum of 8 patients in each dose group.

Eligibility Criteria:
Inclusion Criteria:

Enroll a subject in this study if the subject meets the following inclusion criteria:

* Is at least 18 years of age;
* Has at least one solid pancreatic lesion;
* Is scheduled to undergo surgical resection for suspected PDAC not earlier than 24 hours and not later than 30 days following BR55 administration;
* Provides written Informed Consent and is willing to comply with protocol requirements.

Exclusion Criteria:

Exclude a subject from this study if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed:

* Is a pregnant or lactating female. Exclude the possibility of pregnancy:

  * by testing on site at the institution (serum βHCG) within 24 hours prior to the start of investigational product (IP) administration,
  * by surgical history (e.g., tubal ligation or hysterectomy),
  * by post-menopausal status with a minimum 1 year without menses;
* Has undergone prior systemic therapy for pancreatic cancer;
* Has history of any concurrent malignancy;
* Has history of any clinically unstable cardiac condition including class III/IV congestive heart failure;
* Has had any severe cardiac rhythm disorders within 7 days prior to enrolment;
* Has severe pulmonary hypertension (pulmonary artery pressure \> 90mmHg) or uncontrolled systemic hypertension and/or respiratory distress syndrome;
* Has open and/or non-healing wounds in the chest, abdomen and pelvis;
* Has other systemic vascular abnormalities associated with neovascularization, such as macular degeneration, that in the opinion of the investigator could significantly affect the ability to evaluate the effects of BR55;
* Is participating in a clinical trial or has participated in another trial with an investigational compound within the past 30 days prior to enrolment;
* Has previously been enrolled in and completed this study;
* Has any known allergy to one or more of the ingredients of the IP or to any other contrast media;
* Is determined by the Investigator that the subject is clinically unsuitable for the study;
* Has had major surgery, including laparoscopic surgery within 3 months prior to enrolment;
* Has history of pancreatic surgery (e.g., cyst removal);
* Has acute pancreatic abnormalities (acute pancreatitis or trauma).
Assisted Reproductive Technology Survey (ART Survey)

The purpose of the study is to collate local information to better understand the motivations, accessibility and frequency of assisted reproductive technology (ART) use in the community.

The ART survey study recruitment will last about 6 months with the study completed within 1 year. Study participation is an online survey which takes approximately 3 minutes to complete.

The goal is to apply for future funding to study the metabolic consequences of being conceived with ART.

Eligibility Criteria:
Inclusion Criteria:

* Any individual may complete this survey

Exclusion Criteria:

* No exclusion criteria
Comparison of Diagnostic Accuracies of Various Endoscopic Examination Techniques

Endoscopic diagnosis of lateral spreading tumours (LST) with submucosal invasion is important in guiding the treatment strategy. The use of advanced imaging is not standard clinical practice in China. A clinical trial is now under way comparing the accuracy of narrow band imaging (NBI), endoscopic ultrasonography (EUS) and magnifying chromoendoscopy (MCE) for the diagnosis of LST with submucosal invasion.

Endoscopic diagnosis of lateral spreading tumours (LST) with submucosal invasion is important in guiding the treatment strategy. The use of advanced imaging is not standard clinical practice in China. A clinical trial is now under way comparing the accuracy of narrow band imaging (NBI), endoscopic ultrasonography (EUS) and magnifying chromoendoscopy (MCE) for the diagnosis of LST with submucosal invasion.The final histologic diagnosis was used as the true diagnosis in the present study. By comparing the consistency of histologic diagnosis and preoperative evaluation,the diagnostic accuracies of various endoscopic examination techniques(narrow band imaging , endoscopic ultrasonography , and magnifying chromoendoscopy) was calculated respectively.

Eligibility Criteria:
Inclusion Criteria:

- patients older than 18 years and Less than 65 years patients with endoscopic diagnosis of lateral spreading tumours signed informed consent

Exclusion Criteria:

- patients with serious heart, brain, lung, kidney complications patients with intestinal obstruction previous therapy for colorectal cancer women in gestational and lactational period taking anticoagulants or antiplatelet medications. based on the evaluations of physicians, the patient's condition is not suitable for the clinical trial
Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas

This study is looking at the advantage of establishing surgical drainage for Crohn's fistulas and abscesses prior to starting medical therapy.

Currently the importance of surgically established drainage of Crohn's perianal fistulas prior to medical therapy is controversial. Several retrospective studies have suggested a benefit to this approach. (1, 2) However, there have been no prospective studies performed to answer this important question. This study aims to definitively answer this question. Our hypothesis is that by establishing surgical drainage of all perianal fistulas and abscesses prior to initiation of medical therapy, further abscess formation will be prevented and the rate of durable fistula healing will improve.

Eligibility Criteria:
Inclusion Criteria:

* Male and Female aged 18 years or older;
* A confirmed diagnosis of Crohn's disease and one or more identifiable perianal fistulas;
* Patient's standard of care treatment plan includes the following options: a) surgical intervention with an exam under anesthesia (EUA) by colorectal surgeon, seton placement and drainage of fistula prior to initiating Certolizumab or b) initiating Certolizumab without surgical intervention;
* Patient has had recent colonoscopy to determine disease activity and extent; and
* Patient has had either rectal EUS or pelvic MRI (type of test based on investigator site preference) which has identified one or more perianal fistulas.

Exclusion Criteria:

* Any of Inclusion Criteria is not met;
* Females who are pregnant or breast feeding;
* Anti-TNF use within 6 weeks prior to study entry;
* Patients who cannot take, or refuse to take concomitant immunosuppressive therapy with either azathioprine, 6-mercaptopurine, or methotrexate; Unless patient has been intolerant of these therapies in the past or is contraindicated as determined by the investigator.
* Patients who cannot take, or refuse to take concomitant antibiotic therapy;
* Patients with severe anal stenosis or tenderness which would preclude colonoscopy and / or rectal EUS;
* Patients who cannot take or refuse to take certolizumab;
* Patients with active or latent tuberculosis;
* Patients who have had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to Screening for all non-Crohn's related infections;
* Patients concurrently taking anakinra (Kineret);
* Patients with a history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinomain-situ of the cervix;
* Patients with chronic hematologic problems such as bleeding dyscrasias;
* Patients with a history of demyelinating disease (i.e. multiple sclerosis); and
* Patients with congestive heart failure
Effect of Palm Sugar on Blood Glucose Concentrations

The purpose of this study is to determine by how much, the ingestion of palm sugar increases blood glucose concentrations and what the corresponding glycaemic index is. The investigators estimate that the glycaemic index will be 68 (equal to that of sucrose).


Eligibility Criteria:
Inclusion criteria:

* Healthy: as judged by the participant;
* Age: 18 to 35.

Exclusion criteria:

* Pregnant or lactating females
* Presence of a chronic disease such as diabetes, illness, dysmetabolic syndrome
* 18.5 \< BMI \< 25
* Allergy or intolerance to palms or coconuts
* Weight loss or gain of more then 5 kg in the last two months
* Fasting blood glucose levels \<100 mg/dl or 5.6 mmol/l
* Smokers
* Use of medications other then birth control
* Previous problems with blood sampling
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207).

The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks of follow-up.


Eligibility Criteria:
Inclusion Criteria:

* Participants who have completed the treatment period and the follow up period in CRSwNP lunsekimig parent study, including EOS visit, as per protocol.
* Participants receiving therapy with intranasal mometasone furoate nasal spray (MFNS).
* Participants who are able and willing to participate in this extension study, and to comply with requested study visits and procedures.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

* Prior hypersensitivity reaction to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
* Concurrent participation in any clinical study other than the parent study, including non-interventional studies.
* Participants who, during their participation in the parent study, developed an adverse event (AE) or a serious adverse event (SAE) deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Instrument Assisted Soft Tissue Mobilization Versus Trigger Points Release on Upper Trapezius Trigger Points

Study will be randomized clinical trial. Data will be collected from non probability consecutive sampling technique. Total 30 participants from Ganga Ram Hospital and Care medical centre will be selected and randomly allocated to two different groups i.e Group A and Group B. . Group A will be treated by trigger point release. Group B will be treated by Instrument assisted soft tissue release. NPRS, GONIOMETRY, NDI will be used as outcome measuring tool before and after treatment. Data will be analyzed by using Statistical package for social sciences 25.

Trigger point is defined as a hyperirritable palpable nodule contained in the skeletal muscle fibers. The palpable nodule, also named taut band, is described as a limited number of fibers with an increased stiffness. Trp causes the muscles to week and stiff, leading to reduction in range of movement. MTrP can produce local and referred pain, either on manual compression or spontaneously.

Instrument-assisted soft tissue mobilization (IASTM) is the use of hard tools to manipulate soft tissue and was derived from the Cyriax1 cross-friction massage. It has recently emerged as a popular alternative to traditional manual therapy techniques. Modern-day IASTM instruments vary in material (e.g. stainless steel, plastic) and design and are used to improve a variety of musculoskeletal conditions and associated outcomes.

Manual technique that uses direct vertical pressure to the TP, is a well-established treatment method used to resolve the TP-related pain syndrome. This directed pressure is managed according to the therapist's perception of the tissue resistance of the treated soft tissue or according to the pain perceived by the patient based on a pain scale. Manual therapy is a commonly used treatment for MPS as it has been considered one of the most effective techniques for the inactivation of MTrPs.

Eligibility Criteria:
Inclusion Criteria:

* Patients with neck pain in the upper trapezius muscle
* Tender nodule, constant pain, a jump sign during palpation will be included in this study

Exclusion Criteria:

* Patients with Whiplash injury
* History of neck/shoulder surgery
* Cervical Radiculopathy
* History of malignancy
Effects of Balloon-blowing Exercises in 90/90 Bridge Position With a Ball on Pulmonary Function Among Asthmatic Patients

In asthma, the airways in the respiratory system can experience inflammation and constriction, causing increased difficulty in expelling air during exhalation. This results in disruptions to respiratory parameters, exercise intolerance, and a diminished overall quality of life.Engaging in balloon-blowing exercises while in a 90/90 bridge position with the use of a ball will lead to enhanced pulmonary function and quality of life in individuals with asthma.

Asthma attacks and labored breathing can cause strain and weakness in the diaphragm, the main muscle supporting breathing, as well as the muscles of core.

The study objective is to determine the effects of balloon-blowing exercises in 90/90 bridge posotion with a ball on pulmonary function and quality of life among asthmatic patients.

Eligibility Criteria:
Inclusion Criteria:

* Adults: aged (18-59 years)
* Gender: Both male and females
* Grade1- Grade 4 on Modified MRC dyspnea scale
* Asthma severity ( level 1 mild intermediate, levell 2 mild persistent)

Exclusion criteria:

* Level 3 and above asthmatics or status asthmatics.
* Any congenital deformities of chest wall/ Heart/ Lungs.
* Demonstrated neuromuscular or neurological deficit/ chest wall deformity.
* Cardiopulmonary diseases including coronary artery disease(CAD), Pulmonary HTN, ------Aortic Stenosis, regurgitation, etc.
* Any Autoimmune disease with manifestations of Chest wall/ heart/ Lungs.
* Any recent cardiothoracic or abdominal surgery or sternotomy.
* Recent history of the blunt chest wall or abdominal trauma.
* Unstable hemodynamic parameters (arterial pressure \>140mmhg systolic and \>90mmhg for diastolic).
* Pregnancy
Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer

RATIONALE: Learning about long-term effects in patients with testicular cancer may help doctors plan better treatment and follow-up care.

PURPOSE: This clinical trial is using CT scans to follow patients who have been treated for metastatic testicular cancer.

OBJECTIVES:

* To assess the frequency of relapse or recurrent abnormalities detected by CT scan in patients on long-term follow-up for metastatic nonseminomatous germ cell tumour (NSGCT).
* To assess the utility of CT scan-assessment in these patients.
* To assess the prognostic factors predictive of late relapse in NSGCT.

OUTLINE: This is a multicenter study.

Patients are screened by CT scan of the chest, abdomen, and pelvis for detectable abnormalities or indications of late relapse. Scans are classified as positive or negative, according to standard CT criteria, by a radiologist with expertise in testicular cancer imaging. Patients with negative scans are followed yearly by clinical examination and tumor marker assessment, and every 5 years by CT imaging. Additional follow-up is performed at the discretion of the attending physician. Patients with positive scans undergo confirmation of relapse, whenever possible, by surgical excision or biopsy and treatment is initiated according to best clinical practice. If the follow-up scan is equivocal, patients are advised to have a follow-up scan of the affected region in 6 months.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of metastatic nonseminomatous germ cell tumor (NSGCT) at risk of developing late relapse of residual abnormality

  * Royal Marsden Hospital stage II-IV disease
* Treatment for NSGCT completed within the past 5 to10 years

  * No evidence of disease after completion of chemotherapy, as demonstrated by negative CT scans within the past 3 years

PATIENT CHARACTERISTICS:

* Willing to attend follow-up for five years
* No contraindication to CT imaging

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia

Despite increasing recognition of misophonia, there are currently no evidence-based treatments to help those who are suffering. Therefore, the primary purpose of this study is to assess the acceptability, feasibility, and preliminary efficacy of a treatment for misophonia. This study will be conducted in two phases. In the Phase 1, participants will receive a treatment the investigators believe can help manage symptoms of misophonia: The Unified Protocol. This treatment uses evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with Misophonia. After treatment, patients will provide feedback about their experience. The investigators will use this feedback to revise the treatment as indicated. In Phase 2, participants will receive the revised treatment and provide feedback on their experience. Throughout treatment in either phase, participants will provide daily and weekly information about their symptoms.

The aims of this study are (1) to explore the acceptability and feasibility of the Unified Protocol for individuals who experience Misophonia and (2) to examine whether this treatment helps reduce symptoms associated with Misophonia.


Eligibility Criteria:
Inclusion Criteria:

* Between age 18-65
* Able to read English
* Meet criteria for interfering symptoms of misophonia
* Live in North Carolina

Exclusion Criteria:

* Under age 18 or over age 65
* Current mania
* Current psychotic disorder
* Current anorexia
* Presents with a condition that requires immediate prioritization in treatment (e.g., suicide planning or intent)

Phase 1 participants cannot also participate in Phase 2.
Perioperative Coagulation Management in Cardiac Surgery.

Cardiac surgery is bleeding requiring transfusion surgery .

The haemorrhagic is related to the need to use high doses of anticoagulants to prevent thrombosis of blood . Moreover, this type of surgery is platelets and coagulation factors consumming despite conducting a thorough anticoagulation.

All these changes contribute to increase the need for transfusions during heart surgery.

The main objective of this study is to compare the need for transfusions in patients suffering from bleeding complications after cardiac surgery with a therapeutic algorithm based on the use of ROTEM ® versus standard tests based solely on standard laboratory tests.

100 pateinst (50 in each arm) should be included in this trial.


Eligibility Criteria:
Inclusion Criteria:

* Adults\> 18 years
* Cardiac surgery or heart transplantation with abnormal bleeding regardless the etiology
* given informed consent

Exclusion Criteria:

* Patient supported by a pre or postoperative circulatory technical assistance
Comparison of POC-test-equipment With the Laboratory

We compare two POC-tests (INRario2 and CoaguChek) for the INR with the laboratory. Therefore, we take bloodsamples (capillary and venous blood) and put it on the tool. After the measuring, a number is shown = INR.

We develop a Bland-Altman-plot for the correlation between the tool value and the laboratory value to illustrate the applicability in the clinical daily routine.

Including criteria: ICU-patients from 18-99 years

Eligibility Criteria:
Inclusion Criteria:

18-99 years, ICU patients

Exclusion Criteria:

Lupus erythematodes Anti-Phospholipid-Antikörper
The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients

The purpose of this study is to evaluate the effectiveness and feasibility of the Screening Inventory of Psychosocial Problems (SIPP) in consultation settings with respect to early recognition and treatment of psychosocial distress, communication between patients and physicians, and psychological distress and quality of life in cancer patients treated with radiotherapy (RT).

Background: The Screening Inventory of Psychosocial Problems (SIPP) is a short, validated self-administered questionnaire to identify psychosocial problems in cancer patients. The one page 24-item questionnaire assesses physical complaints, psychological complaints, and social and sexual problems. There is very little known about the effectiveness of using the SIPP in consultation settings.

Aim: The aim of this study is to test the hypothesis that using the SIPP may prevent underdiagnosis of early symptoms reflecting psychosocial problems, should facilitate communication between physicians and patients about psychosocial distress and may contribute to adequate referral to relevant psychosocial caregivers.

Methods: A Cluster Randomized Controlled Trail (CRCT) is developed using a Solomon four-group design (two intervention and two control groups) to evaluate the effects of using the SIPP. Radiotherapists instead of patients are at random allocated to experimental or control groups. All included patients are randomized into the groups with and without pre-measurement. Psychosocial distress, quality of life, patients' satisfaction about communication with their radiotherapist during first consultation and the number and type of referred patients to psychosocial caregivers are assessed. Self-administered assessments are conducted at four times: pre-test before first consultation (T1), and post-tests directly following the first consultation (T2), three months (T3) and one year after (T4) the first measurement. Medical information are gathered from patients' medical records. Furthermore, a process evaluation is carried out.

Relevance: Using the SIPP may lead to a reduction of psychosocial problems and better quality of life, both on the short and long term. If the SIPP proves to be effective, the results of this project may contribute to motivate health care workers to use the SIPP as a standard method for early detection of psychosocial distress in oncology departments in the Netherlands and abroad.

Eligibility Criteria:
Inclusion Criteria:

* Breast Cancer
* Lung Cancer
* Prostate cancer
* Bladder Cancer
* Colorectal Cancer
* Cervix Cancer
* Cancer of endometrium
* Cancer of Skin
* Hodgkin Lymphoma
* Non-Hodgkin Lymphoma
* Must receive radiotherapy treatment (RT)
* 18 years of age or older

Exclusion Criteria:

* Metastases
* Less than 10 fractions of radiotherapy treatment (RT)
* Unable to read, and speak Dutch
* Unable to complete questionnaires